Amgen's trebananib hits main goal in ovarian cancer trial

06/13/2013 | American City Business Journals

Amgen's experimental drug trebananib, or AMG 386, in combination with paclitaxel, achieved the primary goal of a late-stage study by extending progression-free survival in patients with ovarian cancer. Patients who took trebananib survived 7.2 months without their disease worsening compared with 5.4 months for those in the control group.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA